Article Data

  • Views 499
  • Dowloads 128

Original Research

Open Access

Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma

  • M. Milivojevic1,*,
  • V. Boskovic2
  • J. Atanackovic3
  • S. Milicevic3
  • S. Razic4
  • B. Kastratovic Kotlica2

1Center of Medical Biochemistry, Clinical Center of Serbia, Belgrade

2School of Medicine, University of Belgrade, Clinic of Gynecology and Obstetrics, Clinical Center of Belgrade, Belgrade

3Clinic of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade

4Faculty of Pharmacy, Department of Analytical Chemistry, University of Belgrade (Serbia).

DOI: 10.12892/ejgo340116 Vol.34,Issue 1,January 2013 pp.83-85

Published: 10 January 2013

*Corresponding Author(s): M. Milivojevic E-mail: mirjanamilivojevic1@gmail.com

Abstract

The objective of this study was to determine the potential of osteopontin (OPN) and OPN + CA125 (cancer antigen 125) combination in differential diagnosis of the ovarian cancers and non-malignant ovarian disease. Serum and plasma samples were obtained preoperatively from 79 women undergoing surgery for pelvic mass; 48 of them had ovarian carcinoma, and 31 had benign cyst. The samples were analyzed for the levels of OPN and CA125 (using ELISA and CMIA methods) and then compared with the final pathologic results. The median plasma level of OPN in patients with benign and malignant cysts was 356.33 ng/ml and 865.15 ng/ml, respectively (p < 0.001). Receiver operating characteristic (ROC) analysis for plasma OPN revealed the area under the curve (AUC) of 0.838. At the predefined specificity of 90%, OPN showed sensitivity of 62.5%, whereas the combination of OPN + CA125 reached 74.9% at the same specificity.

Keywords

Ovarian cancer; Osteopontin; CA125; Tumor markers.

Cite and Share

M. Milivojevic,V. Boskovic,J. Atanackovic,S. Milicevic,S. Razic,B. Kastratovic Kotlica. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma. European Journal of Gynaecological Oncology. 2013. 34(1);83-85.

References

[1] National Institutes of Health Consensus Development Conference Statement: “Ovarian cancer: screening, treatment and follow-up”. Gynecol. Oncol., 1994, 55, S4.

[2] Holschneider C.H., Berek J.S.: “Ovarian cancer. Epidemiology, biology and prognostic factors”. Semin. Surg. Oncol., 2000, 19, 3.

[3] Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F.: “Pre-and post-translational regulation of osteopontin in cancer”. J. Cell Commun. Signal., 2011, 5, 111.

[4] Nakae M., Iwamoto I., Fujino T., Maehata Y.,Togami Sh., Yoshinaga M., Douchi T.: “Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen CA125 in predicting ovarian cancer”. J. Obstet. Gynaecol. Res., 2006, 32, 309.

[5] Tiniakos D.G., Yu H., Liapis H.: “Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP)”. Hum. Pathol., 1998, 29, 1250.

[6] Ye B., Gagnon A., Mok S.C.: “Recent technical strategies to identify diagnostic biomarkers for ovarian cancer”. Expert. Rev. Proteomics, 2007, 4, 121.

[7] Langmar Z., Nemeth M., Vlesko G.,Kiraly M., Hornyak L., Bosze P.: “HE4-a novel promising serum marker in the diagnosis of ovarian carcinoma”. Eur. J. Gynaecol. Oncol., 2011, 32, 605.

[8] Hwang J., Na S., Lee H., Lee D.: “Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial ovarian cancer”. J. Gynecol. Oncol., 2009, 20, 169.

[9] Kim K., Visinttin I., Alvero A. B., Mor G.: “Development and validation of a protein based signature for the detection of ovarian cancer”. Clin. Lab. Med., 2009, 29, 47.

[10] Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T. et al.: “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass”. Gynecol. Oncol., 2008, 108, 402.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top